Fernández MJR, Despaigne BB, de la Fé VN

Language: Spanish
References: 19
Page: 1262-1266
PDF size: 173.47 Kb.

ABSTRACT

A descriptive and observational study was carried out in patients with acute arterial insufficiency of the limbs, admitted to the Angiology Department of "Dr. Ambrosio Grillo Portuondo" Clinical Surgical Teaching Hospital of Santiago de Cuba, from January 2008 to April 2011, with the purpose of monitoring their progress as for an early diagnosis and treatment. All the members of the series had the classic symptoms of the condition, but the majority did not undergo the examination of arterial pulses in the primary health care, and although more than 50% of them were treated at the first 4 hours after the onset of symptoms, most of them received specialized care between 9 and 24 hours of its manifestation. Similarly, age group of 61 years and over, urban origin, obliterating atherosclerosis (alone or combined with other diseases) prevailed as the clinical entity most associated and surgical revascularization as an initial procedure. A significant percentage of those who were operated before 8 hours saved the limb, but those that were operated after 24 hours of acute onset were amputees.

REFERENCES

1. Esteban JM, Valle A, Pacho J. Epidemiología de la isquemia crítica. Angiología. 1993; 45(3): 91-4.

2. Salmerón FLM. Tratamiento médico de la isquemia aguda de los miembros inferiores. En: Ros Díe E. Novedades farmacológicas y en las vasculopatías. Barcelona: Fundación Uriach; 1998. p. 341-6.

3. Sánchez Chaparro MA, Román García J, Calvo Bonacho E, Gómez Larios T, Fernández Meseguer A, Sáinz Gutiérrez JC, et al. Prevalence of cardiovascular risk factors in the spanish working population. Rev Esp Cardiol. 2006; 59(5): 421-30.

4. Feasby TE, Kennedy J, Quan H, Girard L, Ghali WA. Real-world replication of randomized controlled trial result for carotid endarterectomy. Arch Neurol. 2007; 64(10): 1496-500.

5. Abbott AL, Bladin CF, Levi CR, Chambers BR. What should we do with asymptomatic carotid stenosis? Int J Stroke. 2007; 2(1): 27-39.

6. Steiger E. Dysfunction and thrombotic complications of vascular access devices. J Parenter Enteral Nutr. 2006; 30(1 Suppl): 70-2.

7. Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005; 112(19): 2890-985.

8. Kumana CR, Cheung GTY, Lau CS. Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis. 2004; 63(11). p. 1522-4.

9. Sen S, Moorkerjee R, Jalan R. Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: a case for combined use in hepatorenal syndrome? Gastroenterology. 2002; 123(6): 2160-1.

10. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002:122:923-30.

11. Sharma R. Novel phosphodiesterase-5 inhibitors: Current indications and future directions. Indian J Med Sci. 2007; 61(12): 667-79.

12. Luks AM, Swenson ER. Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. Chest. 2008; 133(3): 744-55.

13. Berez PB. The successful use of phosphodiesterase type 5 inhibitors to treat the syndrome of cor pulmonale and prerenal azotemia with diuresis of anasarca (CorPRADA). South Med J. 2010; 103(2): 116-20.

14. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med. 2009; 6(7): 1794-808.

15. Dudrick SJ. History of vascular access. J Parenter Enteral Nutr. 2006; 30(1 Suppl): 47-56.

16. Bueno TM, Diz AI, Cervera PQ, Pérez Rodríguez J, Quero J. Peripheral insertion of double-lumen central venous catheter using the Seldinger technique in newborns. J Perinatol. 2008; 28(4): 282-6.

17. Cuenca Dardon J. Manual de anestesia en el paciente politraumatizado grave. 2 ed. Editorial Prado. 2007. p. 161-77.

18. Mostaza Prieto JM, Lahoz Rallo C. Tablas para la estimación del riesgo cardiovascular: todavía muchos interrogantes. Med Clin (Barc). 2006: 126(14): 535-6.

19. Lahoz Rallo C, Mostaza Prieto JM. Tablas de riesgo para diabéticos: ¿son realmente necesarias? Med Clin (Barc). 2006; 126(13): 495-6.